What does this research mean for the field?

ddPCR testing of plasma supernatant achieves high overall agreement with tumor KRAS mutation status in lung adenocarcinoma. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

This study aims to compare the effectiveness of ddPCR testing of plasma cfDNA and extracellular vesicles for detecting KRAS mutations in lung adenocarcinoma.

March 13, 2026Cancer Reports0 citationsOpen Access

View Full Paper

Comparative Liquid Biopsy Testing for KRAS Mutations From Plasma Cell‐Free DNA ( cfDNA ) and Extracellular Vesicles in Lung Adenocarcinoma

CZCaeli J. ZahraThe University of Queensland TCTian Mun CheeThe University of Queensland ESEdward K.H. Stephens

Key Points

This study aims to compare the effectiveness of ddPCR testing of plasma cfDNA and extracellular vesicles for detecting KRAS mutations in lung adenocarcinoma.
Used ddPCR testing on plasma supernatant samples for KRAS mutation analysis.
Analyzed the abundance of KRAS in different plasma fractions.
Compared results to tumor KRAS mutation status.
Found high overall agreement between ddPCR results and tumor KRAS mutation status.
Detected varying levels of KRAS in different plasma fractions.

Abstract

We conclude that ddPCR testing of plasma supernatant achieved high overall agreement with tumour KRASmt status. There was varying abundance of KRAS detected in the plasma fractions.

KI fragen

Bookmark

View Full Paper

KI fragen

Bookmark

View Full Paper

Comparative Liquid Biopsy Testing for KRAS Mutations From Plasma Cell‐Free DNA ( cfDNA ) and Extracellular Vesicles in Lung Adenocarcinoma

Key Points

Abstract

Cite This Study

Also Consider

Also Consider